试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-14
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
编号:NCT02715804登记状态:提前终止企业 / 申办者:Halozyme Therapeutics
药物 / 成分:Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)、Placebo、nab-Paclitaxel、Gemcitabine
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-14
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
编号:NCT02718417登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:carboplatin、paclitaxel、Avelumab、Avelumab
登记的停止原因(原文):The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-14
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
编号:NCT03093025登记状态:提前终止企业 / 申办者:Taisho Pharmaceutical R&D Inc.
药物 / 成分:TS-121 10 mg、TS-121 50 mg、Placebo
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
编号:NCT01832727登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Oprozomib、Dexamethasone
登记的停止原因(原文):Enrollment halted during phase 2 to reformulate the investigational product
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
编号:NCT02282163登记状态:提前终止企业 / 申办者:Bracco Diagnostics, Inc
药物 / 成分:sulphur hexafluoride lipid-type A microspheres
登记的停止原因(原文):FDA agreed to early termination due to difficulties enrolling patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
编号:NCT02547220登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:Cinryze®、Placebo
登记的停止原因(原文):Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
编号:NCT02753595登记状态:提前终止企业 / 申办者:Eisai Inc.
药物 / 成分:Eribulin mesylate、Eribulin mesylate、Eribulin mesylate、Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)
登记的停止原因(原文):evolving standard of care and difficulties of enrolling participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU
编号:NCT02903407登记状态:提前终止企业 / 申办者:Duke University
药物 / 成分:Midazolam、Propofol、Dexmedetomidine
登记的停止原因(原文):All enrolled participants completed the study protocol but the study was terminated prior to the goal number of participants due to low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial
编号:NCT03003390登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Enoxaparin
登记的停止原因(原文):Met protocol defined stopping rule for futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
编号:NCT03231228登记状态:提前终止企业 / 申办者:B. Braun Medical Inc.
药物 / 成分:Cefazolin 1 g Infusion、Cefazolin 2 g Infusion
登记的停止原因(原文):Stopped with agreement from FDA.
查看官方原始记录 ↗